Riskpilot← Back to searchSign inGet full accessChosa Oncology AB
ABActiveOrg 5590372271Kungsgatan 6Research and experimental development on natural sciences and engineering · NACE 7210Est. 20150 employees
Revenue 2024
SEK 0
EBITDA margin
—
+37% vs 2023
Equity ratio
92.7%
Financial strength
Net profit 2024
SEK -3M
+46% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -3,3M | +37% |
| Net profit | SEK -3M | +46% |
| Total assets | SEK 56,2M | +2% |
| Equity | SEK 52,1M | +5% |
| Employees | 0 | — |
Legal name
Chosa Oncology AB
Org number
5590372271
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
25 november 2015
Share capital
SEK 12 770 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Föremålet för bolagets verksamhet skall vara att, direkt eller indirekt, utveckla cancerbehandlingar och bedriva därmed förenlig verksamhet samt att äga och förvalta aktier.
Address
Kungsgatan 6
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 2 037 | 1 964 | 1 977 | 73 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −7 778 | −8 469 | −7 706 | −5 227 | −3 271 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −7 778 | −8 469 | −7 706 | −5 227 | −3 271 |
| Net financials | −39 | 107 | −156 454 | −350 | 270 |
| Profit before tax | −7 778 | −8 362 | −164 160 | −5 578 | −3 001 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −7 778 | −8 362 | −164 160 | −5 578 | −3 001 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 182 369 | 174 108 | 25 845 | 54 949 | 56 167 |
| Equity | 179 761 | 171 869 | 7 709 | 49 545 | 52 078 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 2 608 | 2 240 | 18 136 | 5 404 | 4 088 |
| Total debt | 2 608 | 2 240 | 18 136 | 5 404 | 4 088 |
EBITDA margin
-327100000.0%
This company
15.8%
Market median
-2070253265% vs market
20202024
Equity ratio
92.7%
This company
38.2%
Market median
+143% vs market
20202024
Return on equity
-5.8%
This company
18.4%
Market median
-132% vs market
20202024
Net profit margin
-300100000.0%
This company
8.1%
Market median
-3704938372% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.08×
This company
0.62×
Market median
+87% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
PB Chief Executive Officer | Chief Executive Officer | 2020 |
MS Chief Auditor | Chief Auditor | 2024 |
| Former (3) | ||
LJ Chief Executive Officer | Chief Executive Officer | 2020 – 2022 |
MO Chief Auditor | Chief Auditor | 2020 – 2024 |
LO Chief Executive Officer | Chief Executive Officer | 2022 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (6) | ||
| Chairman | 2024 | |
| Board of Directors | 2024 | |
| Board of Directors | 2020 | |
| Board of Directors | 2024 | |
| Board of Directors | 2022 | |
| Board of Directors | 2020 | |
| Former (4) | ||
| Board of Directors | 2022 – 2023 | |
| Chairman | 2022 – 2023 | |
| Board of Directors | 2022 – 2022 | |
| Board of Directors | 2022 – 2023 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Chosa Oncology AB (this company)
CHOSA APSChosa ApsRhovac ApsRHOVAC APSBoard members of Chosa Oncology AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars John Anders Månsson | Chief Executive Officer | 0 companies |
| Magnus Olof Andersson | Chief Auditor | 0 companies |
| Peter Buhl | Chief Executive Officer | 0 companies |
| Maria Sofia Ekelund | Chief Auditor | 0 companies |
| Lars Olof Hedbys | Chief Executive Officer | 0 companies |
| Lars Göran Höckenström | Board of Directors | 0 companies |
| Ingrid Ida Margareta Atteryd Heiman | Chairman | 0 companies |
| Fred Robert Hirsch | Board of Directors | 0 companies |
| Nils Gunnar Gårdemyr | Chairman | 0 companies |
| Ulla Hald Buhl | Board of Directors | 0 companies |
| Bo Anders Ljungqvist | Board of Directors | 0 companies |
| Morten Myrhøj Kristensen | Board of Directors | 0 companies |
| Ulla Cristina Glad | Board of Directors | 0 companies |
| Neil Goldsmith | Board of Directors | 0 companies |
| Claus Frisenberg Pedersen | Board of Directors | 0 companies |